Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (Nasdaq: QDEL) is a global in vitro diagnostics company that regularly issues news on its products, technologies and financial performance. As a manufacturer of diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho generates updates that are relevant to clinicians, laboratory professionals and investors who follow developments in medical diagnostics.
News about QuidelOrtho often covers product clearances and launches, such as FDA 510(k) clearance for the VITROS hs Troponin I Assay to aid in the diagnosis of myocardial infarction, or the availability of the QUICKVUE Influenza + SARS Test, a CLIA‑waived rapid immunoassay that differentiates influenza A, influenza B and SARS‑CoV‑2 from a single sample. These announcements provide insight into how the company is expanding its cardiac, respiratory and point‑of‑care testing portfolios.
The company also issues financial and corporate updates, including quarterly earnings releases, guidance discussions and details of financing arrangements disclosed through press releases and related SEC filings. Investors can track how QuidelOrtho describes its revenue mix, cost‑savings initiatives and capital structure, including credit agreements and refinancing activities.
Another recurring theme in QuidelOrtho’s news flow is educational and thought‑leadership content. Through its Science Bytes podcast, the company highlights topics such as diagnostic trends, early detection of diabetes, the role of informatics in clinical decision‑making and the importance of respiratory testing in urgent care. Episodes feature internal experts and external clinicians and are used to explain how diagnostics intersect with patient care and healthcare economics.
In addition, QuidelOrtho reports on its participation in industry conferences, including events focused on transfusion medicine where it showcases immunohematology products like the MTS DAT Card and ORTHO VISION Platform. For users of this news page, following QDEL news offers a way to monitor product pipeline milestones, regulatory developments, financial disclosures and educational initiatives from a single diagnostics-focused source.
QuidelOrtho reported its Q3 2024 financial results, highlighting a total revenue of $727 million, down from $744 million the previous year, mainly due to higher COVID-19 and influenza revenues in the prior period. GAAP net loss was $20 million compared to $13 million last year, with a GAAP diluted loss per share of ($0.30) versus ($0.19). GAAP operating income was $15 million, down from $26 million, and GAAP operating margin was 2%, compared to 4% previously. Adjusted EPS was $0.85, slightly down from $0.90. Adjusted EBITDA was $171 million, up from $169 million, with a margin of 23.5% compared to 22.7%.
The company reinstated 2024 financial guidance, projecting total revenues of $2.75-$2.80 billion, adjusted EBITDA of $530-$550 million, and adjusted EPS of $1.69-$1.91. QuidelOrtho also emphasized ongoing cost-saving initiatives and leadership enhancements to drive future growth.
QuidelOrtho (Nasdaq: QDEL), a global provider of in vitro diagnostic technologies, has announced its participation in three major investor conferences. The company will engage in fireside chats at the UBS Global Healthcare Conference on November 12, 2024, at 2:00 p.m. ET in Rancho Palos Verdes, the Citi 2024 Global Healthcare Conference on December 4, 2024, at 1:00 p.m. ET in Miami, and the Evercore ISI 7th Annual HealthConX Conference on December 5, 2024, at 10:00 a.m. ET in Coral Gables. Live webcasts and replays will be available through QuidelOrtho's investor relations website.
QuidelOrtho (Nasdaq: QDEL), a global provider of innovative in vitro diagnostic technologies, has announced that it will report its financial results for the third quarter of 2024 on Thursday, November 7, 2024, after the market close. The company will hold a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results.
Interested parties can access the call through the 'Events & Presentations' section of the company's Investor Relations webpage. Presentation materials will be posted at the time of the call. Those unable to access the webcast can join via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) with Conference ID number 117739. A replay of the call will be available on the company's website shortly after the event.
QuidelOrtho (Nasdaq: QDEL) has announced the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective October 7, 2024. Siegrist brings over 15 years of experience in molecular diagnostics, microfluidic platforms, and biomedical engineering. He will lead QuidelOrtho's R&D strategy, focusing on menu expansion and advancing critical platforms.
Siegrist previously served as CTO and Head of Assay Research and Development at Cepheid and co-founded a diagnostics manufacturing company. He will report to Brian Blaser, President and CEO. Werner Kroll, Senior Vice President of R&D, will support the transition until his retirement in March 2025. QuidelOrtho aims to leverage Siegrist's expertise to enhance its position in immunoassay and molecular testing, as well as clinical labs and transfusion medicine solutions.
QuidelOrtho (Nasdaq: QDEL) has appointed Lee Bowman as Chief Human Resources Officer (CHRO). Bowman, with over 25 years of HR leadership experience, will lead QuidelOrtho's human resources strategy and report to CEO Brian Blaser. His role includes overseeing compensation, benefits, recruitment, talent management, and employee development.
Bowman's career includes significant roles at RadNet, Edwards Lifesciences, Levi Strauss & Co., and Target. He holds an MBA from San Diego State University and a BS from Towson University. CEO Blaser highlighted Bowman's expertise in aligning HR strategies with business objectives and fostering an inclusive, high-performing workplace as important for QuidelOrtho's continued growth.
QuidelOrtho (Nasdaq: QDEL) has received FDA 510(k) clearance for its VITROS syphilis assay, now available on VITROS 3600, 5600, and XT 7600 systems in the U.S. This automated assay detects total antibodies to Treponema pallidum in human serum and plasma, aiding in syphilis diagnosis. The launch addresses the growing syphilis epidemic in the U.S., with over 176,000 new cases reported annually and a 36% increase in primary and secondary syphilis since 2021.
The VITROS syphilis assay improves laboratory efficiency by allowing labs to follow the CDC's reverse testing algorithm for syphilis screening. It also reduces costs through earlier disease detection, minimizing the need for external lab referrals. This expansion aims to provide timely and accurate diagnosis, important for effective treatment and disease control.
QuidelOrtho (Nasdaq: QDEL), a global provider of innovative in vitro diagnostic technologies, has announced its participation in two upcoming investor conferences:
1. Morgan Stanley 22nd Annual Global Health Conference in New York, NY on September 5, 2024. President and CEO Brian Blaser and CFO Joseph Busky will participate in a fireside chat at 7:00 a.m. ET.
2. 2024 Baird Global Healthcare Conference in New York, NY on September 10, 2024. Blaser and Busky will participate in a fireside chat at 9:40 a.m. ET.
Live webcasts and replays of both events will be accessible through the 'Events & Presentations' section of QuidelOrtho's Investor Relations webpage.
QuidelOrtho (Nasdaq: QDEL) reported its Q2 2024 financial results. Key highlights include:
- Total revenue of $637 million, down from $665 million in Q2 2023
- GAAP diluted loss per share of ($2.20), compared to ($0.80) in Q2 2023
- Adjusted diluted loss per share of ($0.07), down from $0.26 in Q2 2023
- Adjusted EBITDA of $90 million with a 14% margin
The company announced $100 million in annualized cost-savings initiatives to benefit H2 2024 and H1 2025. QuidelOrtho is focusing on aligning operating expenses with revenue expectations and prioritizing R&D efforts in key growth areas.
QuidelOrtho (Nasdaq: QDEL), a global provider of innovative in vitro diagnostic technologies, has announced that it will report its financial results for the second quarter of 2024 on Wednesday, July 31, 2024, after the market close. The company will hold a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results.
Interested parties can access the call through the 'Events & Presentations' section of QuidelOrtho's Investor Relations webpage. Presentation materials will be posted at the time of the call. Those unable to access the webcast can join via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) with Conference ID 533267. A replay of the call will be available on the company's website shortly after the event.
QuidelOrtho (Nasdaq: QDEL), a leader in in vitro diagnostic technologies, announced its management team's participation in the 44th Annual William Blair Growth Stock Conference. The event is scheduled for June 5, 2024, in Chicago, IL. The company's presentation will take place at 1:20 p.m. CT. Interested parties can access the live webcast and replay on QuidelOrtho's Investor Relations page.